Simon TA, Boers M, Hochberg M, et al. - In this retrospective, observational study of administrative data from three large US healthcare databases that recognize individuals treated with abatacept or other biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), experts evaluated the risk of malignancies and infections in individuals with RA who began abatacept vs other b/tsDMARDs in a real-world setting. Between individuals in the abatacept and other b/tsDMARDs groups, the risks for particular cancers and infections did not vary considerably. The slight rise in total malignancy risk related to abatacept requires further examination. However, these results are constant with the authorized safety profile of abatacept.